Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Study on Efficacy of New Therapeutic Schedules With Peg-Interferon alpha2b and Ribavirin in Patients With Genotype 3 Chronic HCV( Hepatitis C Virus) Infection

NCT01121705 is registered in ClinicalTrials.gov with Casa Sollievo della Sofferenza IRCCS as lead sponsor.

NCT NCT01121705
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01121705 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Study on Efficacy of New Therapeutic Schedules With Peg-Interferon alpha2b and Ribavirin in Patients With Genotype 3 Chronic HCV( Hepatitis C Virus) Infection
Lead sponsor
Casa Sollievo della Sofferenza IRCCS
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2007
Completion date
June 30, 2009
Enrollment
360 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis